An insight into the antifungal pipeline: selected new molecules and beyond.
Invasive fungal infections are increasing in incidence and are associated with substantial mortality. Improved diagnostics and the availability of new antifungals have revolutionized the field of medical mycology in the past decades. This Review focuses on recent developments in the antifungal pipeline, concentrating on promising candidates such as new azoles, polyenes and echinocandins, as well as agents such as nikkomycin Z and the sordarins. Developments in vaccines and antibody-based immunotherapy are also discussed. Few therapeutic products are currently in active development, and progression of therapeutic agents with fungus-specific mechanisms of action is of key importance.
Ostrosky-Zeichner
Luis
L
Division of Infectious Diseases, University of Texas Medical School at Houston, 6431 Fannin, MSB 2.112, Houston, Texas 77030, USA. Luis.Ostrosky-Zeichner@uth.tmc.edu
Casadevall
Arturo
A
Galgiani
John N
JN
Odds
Frank C
FC
Rex
John H
JH
D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D016503:Drug Delivery Systems; D015195:Drug Design; D005657:Fungal Vaccines / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology
D000935:Antifungal Agents; D005657:Fungal Vaccines